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Toxicology in the 21st Century
Toxicology is one of the sciences that have slowly but surely embraced technol ogy and new methods, focusing on high throughput and high content screen ings, omics technologies, and mathematical modeling. Thus, a transition in toxicology-from a traditional reductionist paradigm towards 21st century methods based on human biology and holistic multi-omics studies-is now becoming a reality. With the recent advances in human-cell cultivation tech niques, allowing in vivo-like in vitro long-term functionality, there is a shift in focus towards the mechanistic details of the adverse effects "over time" aimed at a better understanding of the dynamics of biological processes.
In vitro methods, based on human primary cells, cell lines, and genetically modified reporter cell lines, have greatly expanded the scope of in vitro toxi cology. Other significant progress in the area of human-induced pluripotent stem cells (hiPscs) (Asgari et al., 2010; Schwartz et al., 2014; Shinde et al., 2016; Shtrichman, Germanguz and Itskovitz-Eldor, 2013 ) is allowing the application of patient and disease-specific hiPscs (Ghodsizadeh et al., 2010; McCracken et al., 2014; Siller et al., 2013) . Moreover, the tools of precise genome editing with engineered nucleases, such as the zinc finger nucleases (zFNs), the transcrip tion activator-like effecter nucleases (TALE NS) and, more recently, the Clus tered Regularly Interspaced Short Palindromic Repeats ( CRISPR) associated Casg technology ( Gaj, Gersbach and Barbas, 2013; Kim, 2016; Komor, Badran and Liu, 2017) have opened up tremendous opportunities for the development of cell lines, especially those of human origin (Tobita, Guzman-Lepe and de L'Hortet, 2015) . CRISPR/Casg technology was reported for genome editing in hiPscs (Flaherty and Brennand, 201s; Li et al., 2014; Seah et al., 201s; Suzuki et al., 2014) . Another study reported on the simultaneous reprogramming and gene correction of patient fibroblasts (Howden et al., 2015) . Since 2015, more than 3,000 articles were published on studies using CRISPR/Casg genome edit ing, including more than goo articles using the technology in mammalian cells (PubMed, accessed June 11, 2017 ) . With further technological developments, these human in vitro cellular models shall be highly useful in the screening of compounds for personalized medicine, allowing optimum therapy with minimum or no adverse effects, and in the study of adverse outcomes in differ ent strata of population. In addition to high-content screening, where several parameters are measured as simultaneous readouts in single cells ( Gasparri, 2009 ) , high-content imaging will play an important complimentary role in sys tems biology approaches (van Vliet et al., 2014) . High-content platforms have been already used for the screening of compounds (Bale et al., 2014; Sirenko et al., 2014; Tolosa et al., 2014) .
Modem technologies of omics and high-content imaging are resulting in immense data sets which require large-scale data-processing tools. Powerful bioinformatics' tools are also required for data integration and the overarch ing interpretation of biological data from disparate sources. The inherent com plexity of biological systems is a challenge that is expected to be overcome by computational modeling of biological systems. Toxicology is, therefore, aiming at the integration of a tremendous amount of diverse information-at various levels of biological hierarchy (genome, transcriptome, proteome, and metab olome) and biological structure ( organelles, cells, tissues, organs, and organ ism )-with computational tools for understanding and predicting biological behavior ( e.g., adverse effect) under given conditions ( e.g., perturbation due to a toxin). This rejuvenated toxicology in modem terms is referred to as systems toxicology ( see Figure 25 .1 ).
1.1
Systems Toxicolo gy
The term systems toxicolo gy is derived from systems biology and could be de fined as the study of biological systems, using omics technologies, with a focus on the mechanisms underlying complex biological processes, their interac tions and perturbations in response to a toxin combined with mathematical data integration and modeling. Systems toxicology, therefore, aims at under standing and exploring the way that different biological components are or chestrated as an ensemble in cells, tissues, and organisms.
A biological system usually consists of a large number of functionally diverse and/or multitasking components interacting together in a nonlinear fashion in, so-called, biological networks spread over several levels of biological orga nization (Kitano, 2002 homeostasis. Almost 150 years ago, the French physiologist, Claude Bernard, put forward the idea that free life is based on the constancy of the internal en vironment. Later, in 1922, the American physiologist, Walter Canon, described homeostasis as the key principle of life. According to Hans Seyle (1956), since systems are robust, a system under stress will try to achieve a new homeostasis to maintain its functions, until the stress crosses a certain threshold, and the system collapses. Similarly, biological systems exposed to a stressor/toxin will try to adapt and survive. Acute exposure for a short period may constitute a temporary stress that may, or may not, manifest as a toxic effect(s), while the biological system tries to adapt or compensate. However, acute exposure at a very high dose may lead to acute exhaustion of the system's resources to cope and may lead to rapid system breakdown. On the other hand, upon repeated or chronic exposure to low levels of stress, the system inevitably acquires a new homeostasis. This new homeostasis may be accompanied by adverse effects or disease development ( e.g., depression, cancer) over the period of exposure. Upon accumulation of long-term stress, when the system's capacity to main tain altered homeostasis is exhausted, the system will break down, ultimately leading to the extinction of the system. Understanding biological processes means a step towards understanding the mechanisms of adverse effects, which in turn means understanding the mo lecular and functional changes in a system upon perturbation of the system's homeostasis. A mechanistic understanding requires system-wide quantitative measurements of these molecular and functional changes. Recent progress in omics technologies is playing a decisive role in linking system-level understand ing to quantitative molecular knowledge (Ideker, Galitski and Hood, 2001 ). An essential part of systems toxicology is the mathematical modeling of biological responses based on mechanisms and the use of such computational models for predicting responses by changing the parameters of perturbation. Systems toxicology is, therefore, the integration of traditional toxicology with modern techniques of integrated testing strategies, high-throughput screenings, phar macokinetics/pharmacod yn amics knowledge, high-content screenings, omics technologies, in silico tools and modeling. Recent advances in cell-culture techniques, mimicking in vivo organs, are allowing for the acquisition of physiologically relevant information that will enhance pathways-based under standings for the discovery of novel targets and prediction of risks of adverse outcomes. in more than 700 assays and around 300 signaling pathways (Attene-Ramos et al., 2013; Hsieh et al., 2017) . The molecular mechanisms over a series of causal events can be described as the MOA. It is important to distinguish a mechanism of action from the mode of action. A mechanism of action describes the primary chemico-biological in teraction between a compound and a structural moiety in a biological system (Blaauboer and Andersen, 2007 ) . This is more or less equivalent to the mo lecular initiating event in an AOP. The MOA describes functional and structural changes that follow the primary interaction of a compound with its biological target and result in quantifiable changes at the organism level (Blaauboer and Andersen, 2007 ) . The M OA-based paradigm is based on the concept of toxicity pathways. A PoT represents a set of molecular events that ultimately lead to a measurable adverse outcome associated with the stressor/toxin. As such, MOA and AOP are sometimes used in similar contexts.
1.2
Pathways of Toxictty
.3
Adverse Outcome Pathways The concept of AO P was developed in the field of ecotoxicology. Ankley et al. (2010, p. 730) defined AOP as "a conceptual construct that portrays existing knowledge concerning the linkage between a direct molecular initiating event and an adverse outcome at a biological level of organization relevant to risk assessment". The term AOP is a misnomer, since pathways are not intrinsically adverse or non-adverse but they may lead to adverse effects or disease after per turbation. The AOP framework allows the organization and structuring of infor mation for improved decision making in risk assessment (Edwards et al., 2016 ) .
The concept of AOP is now embraced by scientists all over the world, with international efforts for harmonization and guidance on AOP construction and development, such as the Organisation for Economic Co-operation and De velopment ( OECD) guideline (2013) and recently published AOP development strategies, principles, and best practices (Villeneuve et al., 2014a,b ) . AOPs have Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11/11/2019 09:57:0BPM via free access been described for skin sensitization, liver cholestasis, liver steatosis, and fibrosis ( OECD, 2012; Vinken et al., 2013; Willett et al., 2014) . More recently, there are suggestions that the AOP framework can also be used for organizing, structuring, and describing the pathways involved in diseases (Langley et al., 2017; Noor, 2015) . An AOP will begin upon exposure to a compound. The interaction of that compound with the biological target will depend on its physico-chemical properties and could be analyzed using methods of quantitative structure activity relationships ( QSARs ). The interaction of the compound with its bio logical target is the molecular initiating event. This will in tum lead to causal chain of events at different levels of biological organization, with effects at the organelle, cellular, and tissue levels. Depending on the intensity and duration of the exposure, these effects will affect the function( s) of the organ, which will initially try to adapt to the perturbation to achieve a new homeostasis. However, persistent stress will ultimately lead to adverse effect( s) at the organ level (see Figure 25 .3). With time, organ level effects can spread to the whole organism. In epidemiology, many affected organisms will lead to population and ecology effects.
Initially, AOPs were thought to be linear constructs with key events caus ally linked with each other and occurring at different levels of biological or ganization (Landesmann et al., 2013) . However, biological systems are highly complex and interconnected, in addition to being very robust, and show adap tive responses to stress stimuli. Biological processes are nonlinear and highly wired together with feedback loops and cross regulation. Modem AOPs are chemically independent, modular, and connected over networks (Villeneuve et al., 2014a) . The concept of k ey event relationships has been used to explain quantitative connections between several AOPs and more than one adverse 
Organ response
Organ fibrosis Organ failure Cancer outcome ( Figure 25 -4). These connections help to identify gaps and uncertain ties in an AO P. An adverse outcome may also lead to another adverse outcome. For prediction, quantitative response relationships among key events within an AOP are required and make use of weighting and probabilistic and mecha nistic approaches (Becker et al., 2015; Perkins et al., 2015) . It is expected that quantitative Ao P and quantitative Ao P networks will have quantitative k ey event relationships and this may help define anAOP score for the prediction.
Although an AOP is a pragmatic way of organizing information of biologi cal relevance and facilitates causal links with multilevel information, there are many challenges to their wide application. An AOP should not only give information about the structure of the system but also provide important clues (B) an AOP network with multiple pathways and key events (KE) leading to one or more adverse outcomes. The quantitative correlation between two key events (KER) would determine the intensity of the involvement of that pathway.
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Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11/11/2019 09:57:0BPM via free access on the d yn amics of the system. It is highly recommended for an AOP to have direct human relevancy, and an AOP based only on animal data is insufficient. The relationships between molecular initiating events, key events, and adverse outcomes should be predictable. The successful application and adaption of AOPs in toxicology ( especially regulatory toxicology) will depend on the ef fectiveness of an AOP to predict adverse outcomes. Since AOPs are considered living documents that will change with the progressive availability of knowl edge, the development of AOPs will proceed in parallel with their use; which will inevitably, in some cases, pose uncertainties. The more nonlinear linkages there are over multiple pathways, the more challenging the task of deriving correlations for prediction. As with other sciences, there is an urgent need for standardization, harmonization, and development of common language( s) to connect and understand different application domains.
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Preclinical Drug Develo p ment
From the discovery of new therapeutic entities to the marketing of the final product, the drug development process mainly deals with preclinical devel opment and clinical trials of, so-called, investigational new drugs. Preclinical drug development focuses on the proof of efficacy and safety of new drugs. The immense technological advancements of recent years have rendered the drug discovery and development process more expensive than ever. At the same time, the success rates have fallen, the regulatory requirements are becoming stricter, and the competition has become fierce. According to the Tufts Cen ter for the Study of Drug Development, in 2014, the cost of drug development was around us$2.6 billion, with preclinical development costs surpassing us$1 billion (Mullin, 2014) . Only one in ten drugs entering the clinical phase is approved by the us Food and Drug Administration (FDA), according to a recent report (Hay et al., 2014) . The failure of an investigational new drug in the clinical trials may cost billions of dollars (Horton 2004; Lang 2005) . Most investigational new drug failures are due to lack of efficacy and/or clinical tox icity. Human safety issues result in about 20% of failed drugs (Kola and Landis, 2004) . In 2010, a 10-year survey showed that safety issues remained one of the major bottlenecks in drug development (Waring et al., 2015) . The woes of the pharmaceutical industry can continue even after the approval and marketing of a drug, as there is around 5% risk of post-marketing withdrawal due to ad verse effects (Smith and Schmid, 2006) . Liver and cardiac toxicity are the major issues in drug development. Liv er toxicity alone (until 2014) has resulted in most drug withdrawals. The regulatory agencies require the testing of acute and repeated-dose toxicity in animals. Although, the pharmaceutical industry is, at present, using a range of high-throughput in vitro assays ( some accepted by regulatory bodies) in the initial screening of compounds, there are no accepted in vitro models for repeated-dose, long-term toxicity. The next part of the chapter focuses on the limitations of animal models and emerging new models and technology in the assessment of liver toxicity, followed by in silico computational methods in drug development.
Limitations of Animal Models in Liver Toxicity Evaluations
Although in vivo animal testing gives direct evidence of toxicity in a living "in tact" organism and allows experiments not possible in humans, it is limited by several serious drawbacks of scientific, economical, and ethical nature. A ma jor limitation is the poor predictive power of animal studies. This poor transla tion of animal results to humans is mainly due to species-specific differences (Martignoni, Groothuis and de Kante, 2006) . Animals predict only 40% of hu man liver toxicities (Ewart et al., 2014; Olson et al., 2000 ) . Even among differ ent animal species, the correlation is about 60% (Hartung and Daston, 2009 ) , showing differences among test species and the limitation of prediction. The intrinsic differences in animals within the same species provide inconsistent results, especially in the case of oral-dose chronic toxicity. Testing in animals is usually carried out in the highest tolerable doses, which do not reflect hu man exposure. Equally important, even after standard animal testing, 19% of compounds presumably safe in animals, show toxic effects in human clinical trials and are not pursued further (Sacks et al., 2014) . In addition, many drugs proved safe in animal tests and clinical trials, are withdrawn from the market or labeled with black box warnings due to serious side effects. In the past 60 years, there have been more than 450 post-marketing withdrawals of drugs due to hepatotoxicity ( Onakpoya, Heneghan and Aronson, 2016 ) . Species-specific differences are mainly due to differences in the pharmaco kinetic parameters, namely absorption, distribution, metabolism, and elimi nation. Screening in animals is carried out with the assumption that similar reactions of biotransformation and clearance will occur in animals as in hu mans. However, animals differ from humans in the biotransformation of xeno biotics from Phase o ( uptake of compounds mainly via transporters), to Phase I (cYP450 metabolism), Phase II (conjugation reactions), and Phase III (excre tion/eliminations of the parent compound or metabolites or their conjugates mainly via the transporters). It is now well known that not only are there differences in the metabolism of substances between animals and humans, but also many molecular mechanisms of human cellular inju ry are different (Woolbright et al., 2015) .
In addition, due to the characteristics inherent to in vivo testing, such test ing is excessively precautiona ry ; and, therefore, many potential therapeutic compounds are screened out. One such example is aspirin, which is consid ered safe for human beings; it would not have been possible to market aspirin with current methods and criteria for safety (Hartung, 2009 ) . This means that the current methods of screening m ay also possibly screen out compounds that could otherwise be useful in the therapy of human ailments. Other tech nical limitations include, low throughput of animal studies, in addition to prolonged study periods in some cases ( e.g., carcinogenicity study) (Bucher, 2002) .
Although animal testing has provided significant insights into biological processes and has contributed to human safety, the scientific goal of the 21st centu ry should be a move towards human-based in vitro methods, with mod ern tools of systems biology, to bypass the species barrier and to allow better translation.
4
In vitro Models of Liver Toxicity in Preclinical Drug Development
Traditionally, in vitro models refer to cell-cultivation methods of prima ry cells and cell lines, commonly involving plastic or glass cultivation vessels with a cell-culture medium suitable for a given cell type. Wilhelm Roux, a German zoologist, established the basic principles of tissue culture in 1885, by main taining tissues in a warm saline solution for several d ay s. Julius Richard Petri, a German microbiologist, owns the credit of inventing the Petri dish in the early 1900s. Modern two-dimensional ( 2D) cell culture is usually carried out in poly mer culture flasks and dishes of multitude formats. Ross Granville Harrison, an American emb ry ologist, is considered the pioneer of 3D cell culture using the hanging drop method (Nicholas, 1961) . Today, 2D cultivation techniques are well established and cells ( mostly cell lines) of almost all tissues of human or animal origin are available. There are many advantages to the 2D cultivation of cells, such as simplicity; expertise required; low costs; high number of replicates; and, most importantly, applica tion in high-throughput screening in multi-well plates, with the possibility of miniaturization and robotic automation, minimizing human bias and error as well as ensuring high precision. In addition, less material ( cells and culture me dia as well as test substance) is required with fewer ethical concerns. A batte ry of simple and complex 2D in vitro assays can predict up to 80% of human hep atotoxicity (Noor et al., 2009; Vernetti et al., 2017) .
Nevertheless, 2D cultivation of cells involves maintaining the cells in an unnatural and artificial environment, whereby they lose their organ-and tissue-specific architecture and organization. Other factors, such as medium change, cell density to surface ratios, lack of flow and sheer tension, and un physiological oxygen supply are other major limitations. Another commonly encountered problem is the rapid de-differentiation of primary cells, such as the hepatic cells, in 2D cultures, resulting in the loss of functions.
In vivo, cell-to-cell contacts and communication across the extracellular ma trix are ensured within a three-dimensional (3D) arrangement. The extracellu lar matrix regulates cell morphology and gene expression in vivo (Bissell, 2007; Bissell, Hall and Parry, 1982; Le Beyec et al., 2007 ) . A 3D environment influences the epigenetic plasticity of the cells Xu, Spen cer and Bissell, 2007 ) . Conventional 2D hepatic cultures rapidly lose liver-like functionality (Godoy et al., 2013; Paine and Andreakos, 2004) , leading to poor concordance between experimental in vitro data and in vivo data, especially with respect to xenobiotic metabolism and transporter activities. Optimiza tion of the culture medium may help in the maintenance of functions for some time (Klein et al., 2014; Mueller et al., 2012 ) . However, modem in vitro methods are more and more focused on the 3D cultivation of cells as organoids or mi cro tissues that ensure cell-to-cell contacts, cells to be surrounded completely by extracellular matrix, facilitating cell-to-cell communication and signaling (Alepee et al., 2014; Mueller, Heinzle and Noor, 2013) .
3D cultures of primary human hepatocytes and human-cell lines, such as HepRG and HepG2, retain long-term viability and maintain liver-specific functions in vitro (Mueller, Koetemann and Noor, 2011a; Mueller et al., 2011b; Gunness et al., 2013; Mueller et al., 2014; van Grunsven, 2017 ) . 3D cultures ( also called 3D micro tissues, organoids, and organotypic cultures) in microfluidic devices, are termed biochips (Baudoin et al., 2007) , organs on a chip (Bhatia and Ingber, 2014) or body on a chip, where several tissues or organ systems are represented (Marx et al., 2012; Mateme et al., 2015a; Mateme et al., 2015b; Sung et al., 2014) . These emerging technologies allow the study of human physiol ogy and adverse effects in vitro, as they enable analysis of the biochemical and metabolic activities of living cells in functional tissue and organ contexts, while allowing high-resolution, real-time imaging (Bhatia and Ingber, 2014) . Although, such advanced 3D culture techniques demand expertise, and usu ally special equipment/setups, in addition to comparatively higher costs and lower throughputs, they seem to be indispensable for meaningful human biology based science in future.
Much development effort is underway for a high-throughput generation of the 3D cultures as aggregates , micro-patterned co-cultures (Khetani and Bhatia, 2008) and 3D printing . High-content platforms are already used in drug development for the screening of com pounds (Bale et al., 2014; Tolosa et al., 2014) . At the same time, highly-advanced imaging and other techniques (including automated methods for assessing multiple readouts, such as cell viability, shape of the nuclei, cell area, mito chondrial membrane potential, phospholipids accumulation, cytoskeleton integrity, and apoptosis) are playing an important role in the study of biologi cal pathways (Ramaiahgari et al., 2014; Sirenko et al., 2014) . Such high-content and high-throughput platforms are changing the toxicity screening paradigm (Patlewicz et al., 2013) , paving the way towards pathway-based, in vitro only, safety assessment (Adeleye et al., 2014; Kleensang et al., 2014) .
5
Computational in silico Tools
In silico methods such as quantitative structure activity relationships ( QSARs) in predictive toxicology are not new. More than 150 years ago, Cros ( 1863) linked the toxicity of primary alcohols to their water solubility. Crum-Brown and Fra ser (1869) advanced the idea that the biological activity of a compound was linked to its chemical structure. In the 1980s, when pharmaceutical companies were creating libraries of thousands of compounds, methods of QSARs were refined, automatized, and extensively applied. The idea was that the toxicity of a chemical is dependent on specific features of the structure of that chemi cal. Therefore, similar chemical features are expected to share similar mecha nisms of action and could be used for the prediction of activity. Basically, a set of compounds of known activities are used to train computer algorithms to differentiate between active and inactive compounds (Johnson and Maggiora, 1990 ) . QSARs provide a mathematical relationship between a biological activ ity and one or more molecular descriptors able to predict the activity. These molecular descriptors are quantifiable and, therefore, give a quantitative rela tion to the toxicity. Modem QSARs are multidimensional (mQSAR) and include multiple representations of the ligand or protein (Tseng et al., 2012; Vedani, Dobler and Lill, 2006) . QSARs are often used in combination with other methods, such as read-across and weight-of-evidence assessments. Read-across is defined by the European Chemicals Agency (2017, p. 6) as "a technique for predicting endpoint informa tion for one substance (target substance), by using data from the same end point from (an)other substance(s), (source substance(s))". A range of in silico tools are available for grouping the chemicals and read-across (Enoch, Cronin and Ellison, 2011) . Publicly available software include, toxicity estimation soft ware tool (TEST), the 0ECD QSAR toolbox, high-throughput virtual molecule docking (HTVMD ), MetaCore, and the T0PKAt model. QSAR methods are in creasingly predictive in hazard identification for acute toxicity, genotoxicity, mutagenicity, and bioaccumulation. Nevertheless, QSARs and read-across are limited in the prediction of the pharmacokinetic properties of compounds.
Other in silico methods include computational methods for modeling the pharmacokinetics of compounds and linking this to the biological re sponse. Pharmacokinetics deals with the quantification of drug absorption, distribution, and elimination for the investigation and prediction of blood concentration-time profiles. Pharmacokinetic models can be simple to com plex, depending on the level and the quality of information available. Simple models are empirical and can be used for the estimation of clearance and half-life, allowing dosage-regimen calculations (Jones, Mayawala and Poulin, 2013; Klein et al., 201s; Wetmore et al., 2012 ) . Models that are more complex are Physiologically Based Pharmaco-Kinetic (PBPK) models, which are compart ment models. These compartments represent tissues and organ spaces and their volumes. AB early as 1937, Toerell, one of the pioneers of pharmacokinet ics, described the basic principles of a PBPK approach (Teorell, 1937) . However, its mathematical complexity and the lack of physiological data needed for the model were significant challenges to its widespread application for many years.
At present, PBPK models are mechanism based and allow extrapolation from high doses to lower doses, from one species to another, and between dose routes. Traditionally, data is generated from in vivo animal and in vitro animal and human studies (see Figure 25 .5), in an approach originally described by Sobels for anticancer drugs (Sobels, 1977) .
Since PBPK models are based on physiological parameters, it is possible to use them to predict in vivo absorption, distribution, metabolism, and excre tion. PBPK modeling is still heavily dependent on animal studies, and very few clinical applications of PBPK models have appeared. The major reason is the lack of human data for validation. However, in vitro systems can be used, to some extent, for the prediction of distribution, metabolism, and elimination (Poulin, 2013; Poulin et al., 2013a, b; Poulin and Haddad, 2013) . Using a PBPK model, in vitro tests can also provide parameters that allow the prediction of dose-response in vivo. PBPK modeling not only allows simulation of human pharmacokinetics, it also enables in vitro to in vivo extrapolation. For this purpose, quantitative in vitro data, such as data on tissue distribution, rates of metabolism, rates of interactions with biological macromolecules such Kathrin Herrmann and Kimberley Jayne -978-90-04-39119-2 Downloaded from Brill.com11 /11 /2019 09:57:0BPM via free access
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as receptors, changes in cell function and viability, is needed. PBPK model ing combined with other in silico ( chemical-related) and in vitro (biology related) parameter estimations allows for prediction of in vivo exposure equivalent to the in vitro assay concentrations producing an adverse effect. For reliable predictions using such methods, a thorough experimental design with the characterization of the biological system, including the cell model and its characteristics, is essential. Recentl y, simple PBPK models were combined with acute and long-term dose-response data to calculate oral equivalent dos es ( Chang et al., 2015; Hamon et al., 2015; Klein et al., 201s; Rotroff et al., 2010; Wetmore et al., 2012; Yo on et al., 2014) . Models based on a systems biology approach are also being developed (Ide ker et al., 2001) to allow firm anchorage of PBPK/pharmacodynamic models on a mechanistic basis. This new developing area, currently also referred to as quantitative systems pharmacology, focuses on the drugability of targets in bio logical systems. Quantitative systems pharmacology, in fact, follows a systems biology approach to drug discovery, aimed at the underlying mechanisms of drug actions on multiscale systems, using iterative computational modeling (Knight-Schrijver et al., 2016; Vernetti et al., 2017) .
In general, the advantages of in silico methods are low costs, standardiza tion, equipment needs, throughput, and the tremendous possibility of virtual expansion in terms of chemical space, numbers, and biological response sce narios. However, these methods have their own limitations, such as reliability and robustness. These limitations are mainly based on data quality (and in some cases quantity) and the complexity of biological systems. Gene expres sion and metabolic network models, along with integrated, large multiscale models, are computationally demanding, data intensive, and time consuming.
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Toxicology in the Coming Ye ars: Challenges and Pers p ectives
Systems biology-with next generation technologies, such as integrated omics techniques, advanced cell-culture methods, and ass ay s, along with better and faster computational in silica methods-is playing a key role in changing the global mindset towards toxicology. This shift in paradigm will allow for the in tegration of a human knowledgebase, including network information and in vitro assays providing critical key event parameter values, with less emphasis on in vivo animal data (Edwards and Preston, 2008) . For optimal application of systems biology tools, the fundamental construct is to develop adequate and fit-for-purpose in vitro assays to characterize pathway perturbations and pre dict adverse outcomes due to these perturbations. Future in vitro assays will be based on human cells derived from pluripotent stem cells and human reporter cell lines. The two most important comer stones of risk assessment are exposure and concentration response. Systems biology provides the framework for bridging exposure to a compound and its causal adverse outcome (Sheldon and Cohen Hubal, 2009) . It is essential that in vitro data provide relevant information on the concentration response over time. The perturbations and the concentra tion in which they occur should reflect human in vivo exposure and effects. However, extrapolation of in vitro results to humans in vivo is sometimes limited due to the fact that nominal concentrations in the in vitro ass ay s are used without consideration of the exposure magnitude, timing, and duration (Coecke et al., 2013) . Other factors such as in vivo bioavailability and metabolic clearance are not taken into account, in addition to other in vitro specific pa rameters, such as plastic binding, cell-surface binding, compound degradation and evaporation (Groothuis et al., 2015) .
Furthermore, better tools for the characterization of the biological pertur bations leading to adverse effects are needed for a mechanistic understanding of the perturbed pathw ay s. This will require a recapitulation of the toxicity pathway( s) by in vitro assays. In this context, the systems biology approach provides molecular information and key event networks for the comparison of MOA-based pathways. Systems biology measurements will also provide in formation on overlapping events across multiple pathways. Given that there is often a temporal shift in various omics readouts, it is imperative to conduct An ideal shift in paradigm where human-relevant, advanced mechanism based in vitro cells, such as primary human hepatocytes, hiPscs, derived functional hepatocytes, or cardiomyocytes will provide high-quality data for in vitro to in vivo extrapolation ( IVIVE) of human pharmacokinetics (PK)/ pharmacod yn amics (PD), identification of targets, and mechanisms that will ultimately lead to the prediction of adverse effects in humans in vivo.
kinetic studies, so that time resolved data could be obtained. Careful design and control of the system is necessary to obtain high-quality data and to reduce uncertainties inherent to in vitro systems. A fully integrated systems approach would reduce many uncertainties associated with current risk assessment ap proaches. The aim is to obtain human-specific, high-quality data at different molecular levels and integrate these with in silico tools for the extrapolation and prediction of human adverse effects (see Figure 25 .6). Thus, a systems biology approach could help define M OA, species extrapo lation, in vitro to in vivo extrapolation and provide a mechanistic basis for de scribing the susceptibility of certain subpopulations. An integrated approach of human in vitro and in silico methods for in vivo exposure is expected to pro vide a reliable prediction of toxicity. An in vitro system that is designed and characterized to provide human in vivo relevant information will be the key to successful prediction. Combined with qualitative and quantitative knowledge on perturbations in biological pathways over time, this integrated approach could be a powerful tool for in vivo relevant toxicity assessment. Finally, the concept of AOP remains to be developed beyond its limitations and deficiencies to be successful and to gain acceptance by the regulatory agencies in human risk assessment.
Microfluidic systems, using 3D organotypic cultures for compound screen ing, is another area with great promise. In the case of liver, it will additionally allow measurements of pharmacokinetic and pharmacodynamic parameters in vitro. A challenge will be to include more than one organ on such a plat form. Although some systems (see Figure 25 .7) are already reported, they are still limited in their wide application. A pragmatic solution will be to combine organ-type cells, according to the scientific need and the data needed.
The establishment of complex cellular models based on co-cultures is an other active research area with promise in the quantitative understanding of mechanisms in human health and disease. Organs are complex structures and (Ware et al., 2015 ( see Figure 25.8) .
It is hoped that this shift in paradigm will progress towards evidence-based science and personalized medicine, where clinical observations will be used to design advanced in vitro methods based on 3D models, with patient-specific primary or iPsc-derived cellular models (see Figure 25 .9). The omics data from these models is expected to allow biological target identification and valida tion. This information will facilitate personalized therapy for a specific patient depending on the patient's genetic background. The paradigm shift towards clinical, observations-based, mechanistic investi gations in vitro, using advanced tools of cell culture and omics. These should provide potential biomarkers and targets for exploitation in evidence-based personalized therapy and follow-up.
Clinical observations combined with the omics information, mechanisms, and biomarkers will iterate the whole process in modern systems toxicology. The impact of this approach is, no doubt, beyond toxicology in other fields of health, medicine, drug development, and basic sciences. 
